No Data
No Data
Sunflower Pharmaceutical Group (002737.SZ) has a product line led by advantageous varieties such as liver-protecting tablets, stomach Kangling capsules/particles, and mesalazine enteric-coated tablets.
On August 15th, Gelonghui announced that as a leader in adult medicine, Sunflower Pharmaceutical Group's featured areas include treatment for chronic illnesses. With product advantages, the company has formed a segmentation pattern with the digestive system as the dominant category and elderly pain as the core. In terms of the digestive system, the company has a leading product line with liver-protecting tablets, Weikangling capsules/granules, and Mesalazine enteric-coated tablets. The company has extended its product line to cover liver, gallbladder, intestine, and stomach, establishing its product advantages in the field of digestive system medication. In the field of elder pain management, the company is exploring the potential of its existing products.
Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Largest Shareholders Are Private Companies Who Were Rewarded as Market Cap Surged CN¥403m Last Week
Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Calculating The Fair Value Of Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737)
Is Sunflower Pharmaceutical GroupLtd (SZSE:002737) A Risky Investment?
Sunflower Pharmaceutical Group (002737.SZ): Distribute 10 times 1.5 yuan for equity in 2023, with a registration date of June 13.
Sunflower Pharmaceutical Group (002737.SZ) announced on June 4th that the company's annual equity distribution plan for 2023 is: based on the current total share capital of the company, excluding 0 repurchased shares, 584,000,000 shares are used as the base, distributing 15.000000 yuan RMB cash (including tax) per 10 shares to all shareholders. The equity distribution record date for this time is June 13, 2024, and the ex-dividend date is June 14, 2024.
No Data